First Wave BioPharma to advance GI development pipeline with the expected addition of Phase 3 Latiglutenase celiac disease program and Phase 2 clinical programs built around Capeserod and AdrulipaseBOCA RATON, Fla., Dec. 27, 2023 (GLOBE NEWSWIRE) First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced
Hyundai Bioscience announced that Xafty™, a broad-spectrum antiviral drug, can solve RNA virus infections, capable of treating both COVID-19 and Dengue fever or Dengue virus infection". It was announced on October 13, 2023, at IDWeek 2023, a prestigious conference in the field of infectious diseases held in Boston.
Nigeria had sought global help beginning in 2017 for an unprecedented outbreak of monkeypox virus, which continues to this day, with the country detecting 558 suspected cases
Work to develop a new formulation of a common metabolic inhibitor (niclosamide) by David Needham, Professor of Translational Therapeutics in the School of Pharmacy at the University of Nottingham and Professor of Mechanical Engineering and Materials Science at Duke University, could result in a promising early treatment for Covid-19. Click to read more.
New multi-centric, phase-II, randomized, open-label clinical trial evaluates efficacy, safety and tolerability of NIclosamide for the treatment of hospitalized COVID-19 patients.